MA39821B1 - Molécules de liaison spécifiques de l'il-21 et leurs utilisations - Google Patents

Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Info

Publication number
MA39821B1
MA39821B1 MA39821A MA39821A MA39821B1 MA 39821 B1 MA39821 B1 MA 39821B1 MA 39821 A MA39821 A MA 39821A MA 39821 A MA39821 A MA 39821A MA 39821 B1 MA39821 B1 MA 39821B1
Authority
MA
Morocco
Prior art keywords
antibodies
binding molecules
antigen
relates
fragments
Prior art date
Application number
MA39821A
Other languages
English (en)
Other versions
MA39821A (fr
Inventor
Catherine Ettinger
Jodi Karnell
Melissa Damschroder
Partha Chowdhury
Xiaodong Xiao
Ping Tsui
Reena Varkey
Stacey Drabic
Laura Carter
Ronald Herbst
Qun Du
Brian Naiman
Original Assignee
Boston Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288526&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39821(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boston Pharmaceuticals Inc filed Critical Boston Pharmaceuticals Inc
Publication of MA39821A publication Critical patent/MA39821A/fr
Publication of MA39821B1 publication Critical patent/MA39821B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des molécules de liaison de l'il-21, par exemple, des anticorps anti-il-21 et des fragments de liaison à l'antigène de ceux-ci. Dans certains aspects, les anticorps anti-il-21 et fragments de ceux-ci peuvent être des anticorps monoclonaux murins dérivés d'hybridomes et des versions humanisées de ceux-ci. Dans certains aspects, les molécules de liaison, par exemple, les anticorps anti-il-21 et les fragments de liaison à l'antigène de ceux-ci prévus ici inhibent, suppriment ou antagonisent l'activité de l'il -21. En outre, la présente invention concerne des compositions et des procédés pour le diagnostic et le traitement de maladies ou de troubles, par exemple, de maladies ou de troubles inflammatoires, à médiation immunitaire ou auto-immuns associés à la transduction de signal médiée par l'il-21. Dans un mode de réalisation particulier, l'invention concerne des procédés pour traiter ou prévenir une réaction de greffe contre hôte (gvhd) à l'aide de molécules de liaison de l'il-21, par exemple, d'anticorps anti-il-21 et de fragments de liaison à l'antigène de ceux-ci.
MA39821A 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations MA39821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976684P 2014-04-08 2014-04-08
PCT/US2015/024650 WO2015157238A2 (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA39821A MA39821A (fr) 2017-02-15
MA39821B1 true MA39821B1 (fr) 2020-09-30

Family

ID=54288526

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050678A MA50678A (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations
MA39821A MA39821B1 (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050678A MA50678A (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Country Status (23)

Country Link
US (4) US10022443B2 (fr)
EP (2) EP3689325A1 (fr)
KR (1) KR102546611B1 (fr)
CN (2) CN111560071B (fr)
AU (2) AU2015244025B2 (fr)
CA (2) CA3208721A1 (fr)
CY (1) CY1123275T1 (fr)
DK (1) DK3128997T3 (fr)
ES (1) ES2814150T3 (fr)
HR (1) HRP20201377T1 (fr)
HU (1) HUE051676T2 (fr)
IL (2) IL248709B (fr)
LT (1) LT3128997T (fr)
MA (2) MA50678A (fr)
PL (1) PL3128997T3 (fr)
PT (1) PT3128997T (fr)
RS (1) RS60795B1 (fr)
RU (1) RU2708336C2 (fr)
SG (2) SG10201913627TA (fr)
SI (1) SI3128997T1 (fr)
TW (1) TWI665214B (fr)
WO (1) WO2015157238A2 (fr)
ZA (1) ZA201707489B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223283A1 (fr) * 2016-06-22 2017-12-28 Icahn School Of Medicine At Mount Sinai Molécules de liaison au noyau et au mini-noyau du vhc
AU2017394032B8 (en) 2017-01-21 2020-10-22 Guangzhou Hanfang Pharmaceutical Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
PL3661954T3 (pl) 2017-08-03 2022-05-16 Amgen Inc. Muteiny interleukiny 21 i sposoby leczenia
CN109503715B (zh) * 2017-09-15 2023-12-15 科济生物医药（上海）有限公司 Il-4r的融合蛋白及其应用
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113321729B (zh) * 2021-07-01 2022-08-30 东大生物技术(苏州)有限公司 一组il-12单克隆抗体及其医药用途
CN116554323B (zh) * 2023-04-27 2024-02-27 中南大学湘雅二医院 人源化抗il21抗体的开发和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2000029447A1 (fr) 1998-11-19 2000-05-25 Smithkline Beecham Corporation Anticorps antagonistes du rhamm
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
HUP0300919A2 (hu) 2000-03-24 2003-07-28 Micromet Ag Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
US20070092485A1 (en) 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
WO2005075514A2 (fr) 2004-03-10 2005-08-18 Lonza Ltd. Procede de production d'anticorps
CA2566745A1 (fr) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Procedes de traitement du cancer par polytherapie associant il-21 et des anticorps monoclonaux
EP1773394A2 (fr) 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Inhibition de l'activite du recepteur d'interleukine 21
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
KR20070072510A (ko) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
ITRM20040586A1 (it) 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
AU2006341398B9 (en) 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008112543A2 (fr) 2007-03-09 2008-09-18 Wyeth Séquences nucléotidiques et polypeptidiques d'il-21 et d'il-22 de rat, de lapin et de singe cynomolgus
WO2009047360A1 (fr) * 2007-10-11 2009-04-16 Novo Nordisk A/S Anticorps il-21
WO2010055366A2 (fr) * 2007-12-07 2010-05-20 Zymogenetics, Inc. Anticorps monoclonaux anti-il-21 humain
EP2287174B8 (fr) 2008-01-18 2016-12-07 Bio-Rad Laboratories, Inc. Purification améliorée de fragments d'anticorps par chromatographie sur hydroxyapatite
EP2262530A4 (fr) * 2008-03-03 2012-12-05 Dyax Corp Protéines de liaison à métalloprotéinase 12
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CN102137929B (zh) * 2008-06-30 2013-07-10 肿瘤疗法科学股份有限公司 用放射性同位素标记物标记的抗cdh3抗体及其用途
US8580714B2 (en) * 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
AU2011329647B2 (en) 2010-11-19 2015-10-22 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
IL248709B (en) 2020-08-31
AU2019202447B2 (en) 2020-09-10
KR102546611B1 (ko) 2023-06-22
KR20170018814A (ko) 2017-02-20
EP3689325A1 (fr) 2020-08-05
LT3128997T (lt) 2020-10-12
RU2016143378A (ru) 2018-05-08
SG10201913627TA (en) 2020-03-30
CN106794129A (zh) 2017-05-31
WO2015157238A3 (fr) 2015-12-10
SI3128997T1 (sl) 2020-11-30
AU2015244025A1 (en) 2016-11-17
IL273641B (en) 2021-04-29
BR112016029734A2 (pt) 2021-11-16
CY1123275T1 (el) 2021-12-31
CN106794129B (zh) 2020-05-12
AU2015244025B2 (en) 2019-03-21
MA39821A (fr) 2017-02-15
CN111560071B (zh) 2023-09-05
ZA201707489B (en) 2019-06-26
US20200164069A1 (en) 2020-05-28
MA50678A (fr) 2020-08-05
US11529415B2 (en) 2022-12-20
TWI665214B (zh) 2019-07-11
NZ762893A (en) 2023-10-27
EP3128997B1 (fr) 2020-08-05
NZ725735A (en) 2023-09-29
US10588969B2 (en) 2020-03-17
PL3128997T3 (pl) 2020-12-28
US10022443B2 (en) 2018-07-17
DK3128997T3 (da) 2020-08-24
IL248709A0 (en) 2017-03-30
RU2016143378A3 (fr) 2019-01-21
IL273641A (en) 2020-05-31
HRP20201377T1 (hr) 2021-02-19
RS60795B1 (sr) 2020-10-30
CA3208721A1 (fr) 2015-10-15
HUE051676T2 (hu) 2021-03-29
AU2019202447A1 (en) 2019-05-02
RU2708336C2 (ru) 2019-12-05
US20180318416A1 (en) 2018-11-08
ES2814150T3 (es) 2021-03-26
PT3128997T (pt) 2020-09-04
CA2948275A1 (fr) 2015-10-15
WO2015157238A2 (fr) 2015-10-15
US20170173149A1 (en) 2017-06-22
SG11201609178SA (en) 2016-12-29
EP3128997A4 (fr) 2017-12-13
CA2948275C (fr) 2023-10-17
US20230201346A1 (en) 2023-06-29
TW201620934A (zh) 2016-06-16
CN111560071A (zh) 2020-08-21
EP3128997A2 (fr) 2017-02-15

Similar Documents

Publication Publication Date Title
MA39821B1 (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
FR21C1028I1 (fr) Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
NO20063986L (no) Anti-CD-38-humane antistoffer og anvendelse derav
SA114360064B1 (ar) طرق وأجسام مضادة معارضة ضد مستقبل il-7
MA40913A (fr) Conjugués anticorps-médicament
TNSN07398A1 (fr) Anticorps contre la p-cadherine
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MA33387B1 (fr) Polypeptides et procede de traitement
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
TNSN04078A1 (fr) Antibodies to cd40
JP2017518258A5 (fr)
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MX2018012939A (es) Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas.
MA38161A1 (fr) Anticorps anti-bmp-6
WO2019016247A3 (fr) Agents, utilisations et procédés de traitement
MX2021012769A (es) Anticuerpos bloqueadores cd73.
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
BR112022002142A2 (pt) Anticorpos anti-bdca-2
WO2021058795A3 (fr) Domaines de liaison à l'antigène associés à des cellules sénescentes, anticorps et récepteurs antigéniques chimériques les comprenant, et leurs utilisations